[{"id":"e1ab9724-6bf9-4432-b02c-3c4942410528","acronym":"","url":"https://clinicaltrials.gov/study/NCT02947165","created_at":"2021-01-18T14:28:07.532Z","updated_at":"2024-07-02T16:36:17.808Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.","source_id_and_acronym":"NCT02947165","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8","pipe":" | ","alterations":" TILs","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • nisevokitug (NIS793)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 06/18/2021","primary_completion_date":" 06/18/2021","study_txt":" Completion: 06/18/2021","study_completion_date":" 06/18/2021","last_update_posted":"2022-01-31"}]